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Abstract: A validated high-performance liquid chromatographic (HPLC) method for determination of phenytoin (PHN), 
para-hydroxy metabolite of phenytoin (POH) and sildenaﬁ  l (SIL) in rabbit plasma is described. The method is based on 
extraction on Sep-Pak C18 solid support using ethyl acetate and ether as eluents and monitoring at 220 nm. The extracted 
samples were analyzed by HPLC using Agilent Zorbax Extended C18 column (150 mm × 4.6 mm internal diameter) and 
isocratic elution with a mobile phase consist of 29% acetonitrile and 71% sodium acetate solution (0.02 M, pH 4.6). The 
method was fully validated for linearity and range, selectivity, precision, stability, recovery, and robustness. The linearity 
of the method was in the range of 0.15 to 39 μg /ml for PHN and 0.15 to 33 μg/ml for both POH and SIL. Limits of detec-
tion (LOD) of PHN, POH, and SIL were 0.15 ± 0.01, 0.15 ± 0.01, and 0.15 ± 0.01 μg/ml, respectively. The % recovery of 
PHN, POH, and SIL from rabbit plasma were, 101.88 ± 0.12, 99.16 ± 0.25, and 99.49 ± 0.33, respectively. The method was 
applied on plasma collected from rabbits at different time intervals after receiving 30 mg/kg PHN-Na with (and without) 
8 mg/kg SIL citrate.
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Phenytoin (5,5-Diphenylhydantoin, PHN) is one of the most commonly prescribed anticonvulsant drugs 
in the treatment of epilepsy (Fig. 1) (Leduc, 2002). Unfortunately, PHN has narrow therapeutic window, 
and careful monitoring of the drug-plasma level is necessary during therapy to avoid undesirable effects 
(Leduc, 2002). While 10% of healthy men had sexual dysfunctions, male epilepsy patients experience 
sexual problems in 40%–70% of the cases (Bone and Janszky, 2006; Stimmel and Gutierrez, 2006; 
Montouris and Morris, 2005; and Smaldone et al. 2004). Sildenaﬁ  l citrate (Viagra®) is widely used as 
prescribed or non-prescribed agent for management of erectile dysfunction (Bone and Janszky, 2006). 
Assessment of potential pharmacokinetic interaction PHN and SIL awaits evaluation (Stimmel and 
Gutierrez, 2006). Therefore, the present work is designed to develop an accurate and precise analytical 
method to determine PHN in plasma in case of concomitant administration of SIL. The developed 
method is useful to explore the impact of sildenaﬁ  l citrate administration on the pharmacokinetic behav-
ior of PHN in human. Many analytical methods have been reported for the analysis of PHN and its 
metabolites (Bereczki et al. 2001; Guan at al. 2000; and Maya et al. 1992) and PHN in combination 
with other antiepileptic drugs in plasma (Vermeij and Edelbroek, 2007; Bugamelli et al. 2002; and Bhatti 
et al. 1998). Frequently published methods were included; high performance liquid chromatography 
(Vermeij and Edelbroek, 2007; Bugamelli et al. 2002; and Bhatti et al. 1998), thin layer chromatography 
(Simon et al. 1971, and Rao and Mclennon, 1977), gas chromatography (Queiroz et al. 2002), ﬂ  uores-
cence polarization immunoassay (Lu-Steffes et al. 1982), and spectrophotometry (Rezaei et al. 2005). 
The extraction of PHN has been described by many publications which include solid-phase extraction 
(SPE) on C18 column (Guan at al. 2000; Vermeij and Edelbroek, 2007; and Bugamelli et al. 2002). SPE 
on molecularly imprinted solid-phase (Bereczki et al. 2001) or liquid-liquid extraction (Guan at al. 
2000). The percentage recoveries of PHN from plasma were varied from 60%–94% using SPE. On the 
other hand, many chromatographic methods have been reported for the determination of SIL and its 
major metabolite in plasma using different detection methods (Ghazawi et al. 2007; Wang et al. 2005; 
and Cho et al. 2003). Because of the big differences in the physiochemical properties, metabolic fat, 
and dosing of both, PHN and SIL (Moffat et al. 2004), it was necessary to develop an HPLC method 62
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capable for the analysis of this combination in one 
run. In addition to the need of developing a suitable 
extraction procedure to recover both PHN and SIL 
in high yield.
Experimental Section
Chemicals and reagents
Phenytoin sodium was purchased from Spectrum, 
Gardena, NJ, U.S.A. Phenobarbitone sodium 
(In St) was purchased from EVANS Medical LTD, 
Liverpool, England. Sildenaﬁ  l citrate was obtained 
as gift from Sanoﬁ  , Jeddah, Kingdom of Saudi 
Arabia. Phenytoin para-hydroxy metabolite (POH) 
was synthesized in our lab and checked for purity 
by spectral and chromatographic methods (Melton 
and Henze, 1947; and Claesen et al. 1982). All 
solvents were of HPLC or spectroscopic grade. All 
other materials were of Analar grade (sodium 
acetate, sodium hydroxide, formic acid, acetic acid 
100%, diethylamine, and triﬂ  uoroacetic acid). 
Dosing, feeding and sample collection were carried 
in our toxicology laboratory. Rabbit plasma sam-
ples were kept at −20 °C until use.
Equipment
The HPLC system consisted of an Alliance Waters 
separations module 2695, waters 2996 Photodiode 
array detector (Milford, MA, U.S.A.) set to 220 nm. 
Column heater was set to temp 25 ± 2 °C. HPLC 
system control and data processing was performed 
by Empower software (Build 1154, Waters). Screw 
capped V-shaped vials (capacity, 300-μl) were used 
(Alltech, GmbH, Unterhaching, Germany). Digital 
micro-transfer pipettes 5–250 μl (Brand, Wertheim, 
Germany). Sep-Pak C18 extraction columns were 
purchased from Waters Corporation, Milford, MA, 
U.S.A. (part #: WAT051910).
Chromatographic conditions
Analytes were separated on Agilent Zorbax 
Extend-C18, 150 × 4.6 mm, 80Å, 5 μm and 
protected with pre-column: Agilent Zorbax 
Extend-C18, 4.6 × 12.5 mm, 80Å, 5 um (Agilent 
Technologies, Palo Alto, CA, U.S.A.). The mobile 
phase was composed of 29% acetonitrile and 71% 
sodium acetate (0.02 M adjusted to pH 4.6 with 
acetic acid) and pumped at a flow rate of 
1.0 ml/min. The analytical column and pre-column 
were kept at 25 ± 2 ºC. The analytical column was 
Figure 1. Chemical structure of the investigated substances.
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washed with acetonitrile for 20 minutes after each 
ﬁ  ve runs.
Standard and calibration solutions
Standard stock solutions of PHN-sodium and SIL 
citrate were prepared separately in water; however, 
a standard stock solution of POH was prepared in 
acetonitrile, to give concentrations of 2.6, 1.2 and 
1.5 μg/μl, respectively. The internal standard (In 
St) solution was prepared by dissolving 25 mg 
phenobarbitone sodium in 10 ml water, and 1 ml 
from this solution was further diluted to 10 ml with 
acetonitrile to give a concentration of 250 ng/μl. 
Appropriate dilutions in acetonitrile were prepared 
from each stock solution to obtain a mixtures of 
the calibration standards containing PHN sodium, 
POH and SIL citrate spanning the range of 
1.1–78.0, 1.0–66.0 and 1.0–68.0 ng/μl, respec-
tively. A volume of 100-μl from four strengths of 
the calibration standard solutions, covering all 
range, were spiked in blank rabbit plasma to pre-
pare the quality control (QC) samples. The QC 
samples were divided in small aliquots and stored 
at −20 °C until use. A sample volume of 200 μl of 
each QC sample was extracted and analyzed at 
time intervals of; 0, 10 and 30 days. All plasma 
extracts were spiked with 50 μl internal standards 
solution (250 ng/μl phenobarbitone sodium in 
acetonitrile) before the step of drying.
Calibration curve in plasma
The Sep-Pak C18 cartridges were ﬁ  tted in a 25-ml 
plastic syringe. About 3-ml volume of water purged 
throughout the column, and the air was forced to 
pass through the column to remove any unbound 
water. A volume of 200 μl plasma was transferred 
to the side bottom of the syringe, spiked with 100 μl 
of each calibration standard solution mixture 
basiﬁ  ed with 100 μl of diethylamine (5% in ace-
tonitrile). The sample was thoroughly swirled and 
forced onto column using syringe piston. The Sep-
Pak columns were detached from the syringe and 
a compressed air was allowed to pass through the 
column for 30 seconds in the elution direction to 
remove extra plasma liquid. The Sep-Pak columns 
were then attached again to the syringe and a vol-
ume of 10-ml of ethylacetate was poured into the 
syringe column and allowed to ﬂ  ow through the 
Sep-Pak column with approximate ﬂ  ow rate of 
2 ml/min. A volume of 100 μl of triﬂ  uoroacetic 
acid (5% in acetonitrile) was added onto the 
extraction column, and then a volume of 10 ml of 
diethyl ether was added and allowed to flow 
through the Sep-Pak column with approximate 
ﬂ  ow rate of 2 ml/min. The extracts were combined 
in test tube containing 50 μl of In St and dried with 
gentle stream of nitrogen gas at 40 ºC. The residues 
were reconstituted with 150 μl acetonitrile, vor-
texed for 0.5 min, 150 μl sodium acetate (0.02 M, 
pH 4.6), vortexed for 0.5 min, and transferred to 
300-μl autosampler vials with Pasteur pipette. A 
volume of 50 μl was injected for HPLC analysis. 
The generated chromatograms were recorded and 
integrated with Empower WATERS software. The 
calibration curves corresponding to POH, SIL and 
PHN were drawn to calculate regression coefﬁ  cient, 
slope, and intercept. The percentages of peak areas 
ration of the corresponding drug to In St were 
plotted versus concentrations in ng/μl.
Drug recovery from plasma
The Sep-Pak C18 cartridges were ﬁ  tted in a 25-ml 
plastic syringe. A volume of 200 μl plasma was 
transferred and mixed with, 100 μl standard solu-
tion mixture containing PHN, POH, and SIL (78, 
66 and 68 ng/μl, respectively). Then the sample 
was extracted as described under title calibration 
curve in plasma using phenobarbitone sodium as 
internal standard. The same procedures were 
repeated using plasma spiked with PHN, POH and 
SIL (1.1 to 33.0 μg/ml, from each). The procedures 
were repeated three times for each concentration 
level.
Animal treatment and sample 
preparation
Nine Male Albino-rabbits were randomly selected 
for this study. The average weight of rabbits was 
ranged from 1.0 to 1.5 kg. The rabbits were kept 
under standard feeding and housing conditions 
along the experiment. A dose of 30 mg/kg of phe-
nytoin sodium (dissolved in 4 ml sterile water) was 
given intra-peritoneal once daily (od) for seven 
days. On day 7, blood samples were collected at 
times 0, 0.1, 1, 2, 3, 4, 6, 12 and 24 hr after the 7th 
dose. From day 8 to 14, PHN sodium was co-
administered with oral SIL citrate, 8 mg/kg, od. 
On day 14, blood samples were collected at the 
same time points. Blood samples were kept on 
citric acid in a refrigerator at −20 °C till the time 
of analysis. Samples were centrifuged for 64
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10 minutes at 15000 rpm; plasma was harvested 
and immediately frozen at −20 °C until use.
Determination of phenytoin in rabbit 
plasma samples
The Sep-Pak C18 cartridges were ﬁ  tted in a 25-ml 
plastic syringe. About 3-ml volume of water purged 
throughout the column, and the air was forced to 
pass through the column to remove any unbound 
water. A volume of 200 μl plasma was transferred 
to the side bottom of the syringe and basiﬁ  ed with 
100 μl of diethylamine (5% in acetonitrile) and 
extracted as described under title calibration curve 
in plasma using phenobarbitone sodium as internal 
standard. A volume of 50 μl was injected for HPLC 
analysis. The sample content was calculated from 
the calibration curve considering that the% 
recovery is about 100%.
Calculations
The amount of PHN was calculated from the cor-
responding calibration curve as ng/μl (of the ﬁ  nal 
injected solution) and multiplied by 1.5 to get the 
amount as μg/ml of plasma. The para-hydroxy-
metabolite of PHN was not monitored because it 
is predominantly excreted as glucuronide conjugate 
(Moffat et al. 2004).
Results and Discussion
Chromatographic variables
The best chromatographic conditions achieved are 
described at the experimental part. Enough separa-
tion between all drugs investigated with acceptable 
chromatographic performance parameters was 
obtained (retention time, capacity factor, resolu-
tion, tailing factor, theoretical plates, and selectiv-
ity coefﬁ  cient). The retention time of SIL peak was 
critically affected by the variation of pH than In 
ST, PHN and POH. At pH 3.0 ± 0.6 an overlap 
between SIL and POH was observed. Also, at 
pH 3.0 ± 0.6 band broadening of SIL was observed. 
Bad resolution with band broadening of In St, PHN 
and POH with more retarded SIL peak if sodium 
acetate solution (71%, pH 4.6) replaced with for-
mic acid (0.05% adjusted to pH 4.6 with 1M 
NaOH). Also, bad resolution with band broadening 
of all peaks was observed upon using methanol 
(29%–55%) instead of acetonitrile.
Selectivity, precision and performance 
parameters
Upon application of the chromatographic conditions 
mentioned in the experimental part, a complete 
separation between all investigated substances and 
biogenic plasma constituents was observed (Fig. 2). 
The chromatographic performance parameters of 
the drugs extracted from rabbit plasma are shown 
in Table 1. The RSD values of all chromatographic 
parameters were not more than 1.5%.
Linearity and range
A linear HPLC response of percentage peak area 
ratio of drug to internal standard peak areas for 
Figure 2. Representative chromatograms of blank plasma extract 
(a), standard calibration mixture (b)*, and rabbit plasma extract after 
2 hours (c)
† and after 12 hours from receiving PHN and SIL (d)
‡. 
(PHN at 10.12 min, POH at 3.83 min, SIL at 8.29 min, and In St at 
4.76 min).
*POH, SIL and PHN amounts, 15, 20 and 25 ng/μl, respectively.
†SIL and PHN amounts, 0.19 and 14 μg/ml, respectively.
‡POH and PHN amounts, 3.6 and 2.2 μg/ml, respectively.
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PHN, POH, and SIL were observed over the range, 
0.15–39, 0.15–33, and 0.15–34 μg/ml, respectively. 
The calibration parameters of the investigated 
compounds in rabbit plasma are listed in Table 2. 
The values of RSD of limit of quantitation (LOQ) 
and detection (LOD) were relatively high but 
within the acceptable range as per the Food and 
Drug Administration guidelines (did not exceed 
20%) (FDA, 2001).
Precision and accuracy
Within- and between-day precision and accuracy 
were evaluated by analyzing six replicates of qual-
ity control samples at four different concentrations 
of PHN, POH, and SIL (Table 3). Precision was 
expressed as the coefﬁ  cient of variation, though 
accuracy was presented as a percent error (relative 
error), [(observed concentration—nominal con-
centration)/nominal concentration] × 100]. Within- 
and between-day relative standard deviations were 
less than 3.0%. Accuracy was within 7.2% for low 
concentrations and 2.0% for high concentration 
levels when compared with nominal concentra-
tions. The results indicate that the method is reli-
able, reproducible, and accurate.
Recovery and stability (QC samples)
The precisions of % recoveries of PHN, POH, and 
SIL from plasma were calculated from the corre-
sponding calibration curve of each. The % recover-
ies of PHN, POH, and SIL from plasma were, 
101.88 ± 0.12% (n = 6; RSD = 0.11%), 99.16 ± 
0.25% (n = 6; RSD = 0.29%), 99.49 ± 0.33% (n = 6; 
RSD = 0.33%), respectively. The recovery of POH 
was relatively low; however, it was enhanced by 
reducing the wash volume from 20 ml to 3 ml. 
Also, the spiking volume was considered. About 
84% of SIL was recovered from plasma upon using 
diethyl ether and triﬂ  uoroacetic acid, however, 
complete recovery was obtained upon using ethyl 
acetate alkalinized with diethylamine. Within and 
between day precision and accuracy data for deter-
mination of PHN, POH, and SIL in spiked plasma 
are listed in Table 3.
The stability of the investigated substances in 
spiked rabbit plasma was investigated through three 
freeze—thaw cycles of the QC samples during the 
storing period of 0, 10, 30 days at –20 °C. All 
investigated substances were considered stable in 
rabbit plasma after three freeze—thaw cycles at 
nominated concentrations. 101.2% (n = 6; RSD = 
0.10%), 99.4% (n = 6; RSD = 0.27%), 99.1% 
Table 1. The chromatographic performance parameters* of the drugs extracted from rabbit plasma using 
Sep-Pak C18.
Name RT  (min) Area
† (RSD)  Area (%)  Width (sec)  K’  α R  (RSD)  As  N
POH 3.913  2807047  1.68  0.88  2.91      1.31  4522
   (0.23)           
In St  4.857  1668278  –  0.83  3.86  1.32  3.87  1.24  6365
   (0.03)        (0.03)   
SIL 8.007  2538179 1.52  1.58  7.01  1.82  8.96  1.48  5203
   (0.12)        (0.10)   
PHN 10.346  3960490  2.37  1.17  9.35  1.33 5.24  1.13  9309
   (0.07)        (0.01)   
*K’ capacity factor; α, selectivity coefﬁ  cient; R, USP resolution; and As, peak asymmetry; N, USP plate count. All parameters were calculated 
as per United States Pharmacopoeia.
†(Concentrations, 0.36, 0.26 and 0.23 μg/ml of PHN, POH and SIL, respectively).
Table 2. Calibration parameters of the investigated compounds in rabbit plasma.
Name Calibration  range LOQ  as  μg/ml LOD  as  μg/ml Slope
† Intercept
† R
2†
 ( μg/ml) (RSD)  (RSD)
PHN 0.15–39  0.15  (7.4)  0.050  (8.3)  2.180  0.950  0.998
POH 0.15–33  0.15  (7.6)  0.050  (7.8)  2.672  −0.300 0.997
SIL  0.15–33  0.15 (9.3)  0.005 (12.3)  2.680  0.278  0.999
†Calibration parameters calculated as a function of x = amount of PHN as ng/μl of the injected solution, and Y = % of peak area ratio of PHN 
to In St. The x values were multiplied by 1.5 to get the drug amount as μg/ml.66
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(n = 6; RSD = 0.34%), of PHN, POH, and SIL, 
respectively. Results of the stability experiments 
indicated that investigated substances in the plasma 
samples were stable for at least 1 month when 
stored at –20 °C.
Determination of phenytoin in rabbit 
plasma samples
The developed method of analysis was applied for 
determination of PHN in rabbit plasma in presence 
and absence of SIL. No interference from endog-
enous plasma substances, SIL or POH. The 
amounts of PHN recovered (as μg/ml) from rabbit 
plasma were plotted versus time in hours. Figure 3 
shows the PHN plasma curve in both cases. The 
pharmacokinetic proﬁ  le of PHN was not calculated 
due to small number of animals used. However, 
this method could be applied for the study of the 
impact of SIL on the pharmacokinetic of PHN 
using large number of animals and suitable phar-
macokinetic statistical model.
Conclusion
The described HPLC method is selective, precise, 
and sufﬁ  ciently suitable for the analysis of PHN 
in presence of SIL, in rabbit plasma. The extraction 
procedure is characterized by its precision and high 
recovery yield of PHN, POH, and SIL using two 
step extractions on Sep-Pak C18 columns. Samples 
could be analyzed by HPLC within only 15-min 
Figure 3. Phenytoin plasma concentration versus time determined 
following receiving 30 mg/kg of PHN ( ) or 30 mg/kg PHN with 
8 mg/kg SIL (– – –) (average data of 9 animals).
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Table 3. Within and between day precision and accuracy for determination of PHN, POH and SIL in spiked rab-
bit plasma.
Nominal
concentration 
(μg/ml)
Within – day Between – day
Observed 
Concentration*
as μg/ml ±SD
CV
† (%) Relative 
error (%)
Observed 
Concentration*
as μg/ml ±SD
CV
† (%) Relative 
error (%)
PHN 3.00 2.97 ± 0.07 2.35 1.01 3.06 ± 0.04 1.31 1.96
6.00 5.95 ± 0.12 2.02 0.84 5.97 ± 0.11 1.84 0.50
18.00 17.84 ± 0.47 2.63 0.90 17.88 ± 0.50 2.79 0.67
39.00 38.25 ± 1.05 2.74 1.96 38.32 ± 0.96 2.51 1.77
POH 3.00 2.74 ± 0.08 2.86 7.14 2.84 ± 0.08 2.82 5.63
6.00 5.79 ± 0.11 1.90 3.63 5.74 ± 0.11 1.92 4.53
18.00 17.90 ± 0.50 2.79 0.56 17.68 ± 0.50 2.83 1.81
33.00 31.81 ± 0.81 2.55 3.74 32.50 ± 0.81 2.49 1.54
SIL 3.00 3.11 ± 0.08 2.57 3.54 2.89 ± 0.08 2.77 3.81
6.00 5.81 ± 0.07 1.20 3.27 5.94 ± 0.07 1.18 1.01
18.00 17.74 ± 0.71 2.31 1.47 17.66 ± 0.41 2.32 1.93
33.00 32.60 ± 0.72 2.21 1.23 32.80 ± 0.72 2.20 0.61
*Mean (standard deviation), n = 6.
†CV = coefﬁ  cient of variation.67
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run time. The developed method could be applied 
for the study of the impact of SIL on the pharma-
cokinetic of PHN on epileptic patients.
Acknowledgement
Authors acknowledge the Deanship of scientiﬁ  c 
research of King Abdulaziz University, Jeddah, for 
sponsoring this work.
References
Al-Ghazawi, M., Tutunji, M. and Aburuz, S. 2007. Simultaneous determi-
nation of sildenaﬁ  l and N.-desmethyl sildenaﬁ  l in human plasma by 
high-performance liquid chromatography method using electro-
chemical detection with application to a pharmacokinetic study. 
J. Pharm. Biomed. Anal., 43:613–8.
Bereczki, A., Tolokán, A., Horvai, G., Horváth, V., Lanza, F., Hall, A.J. and 
Sellergren, B. 2001. Determination of phenytoin in plasma by 
molecularly imprinted solid-phase extraction. J. Chromatogr., 
930:31–8.
Bhatti, M.M., Hanson, G.D. and Schultz, L. 1998. Simultaneous determina-
tion of phenytoin, carbamazepine, and 10,11-carbamazepine epoxide 
in human plasma by high-performance liquid chromatography with 
ultraviolet detection. J. Pharm. Biomed. Anal., 16:1233–40.
Bone, B. and Janszky, J. 2006. Epilepsy and male sexual dysfunction: etiol-
ogy, diagnosis and therapy. Ideggyogy Sz., 59:148–52.
Bugamelli, F., Sabbioni, C., Mandrioli, R., Kenndler, E., Albani, F. and 
Raggi, M.A. 2002. Simultaneous analysis of six antiepileptic drugs 
and two selected metabolites in human plasma by liquid chromatog-
raphy after solid-phase extraction. Anal. Chim. Acta., 472:1–10.
Cho, J.Y., Lim, H.S., Yu, K.S., Shim, H.J., Jang, I.J. and Shin, S.G. 2003. 
Sensitive liquid chromatography assay with ultraviolet detection for 
a new phosphodiesterase V inhibitor, DA-8159, in human plasma 
and urine. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 
795:179–86.
Claesen, M., Moustafa, M.A., Adline, J., Vandervorst, D. and Poupaert, J.H. 
1982. Evidence for an arene-oxide-NIH shift pathway in the metabolic 
conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin 
in the rat and man. Drug Metab. Dispos., 10:667–71.
FDA, Food and Drug Administration, 2001. Center for Drug Evaluation 
and Research (CDER), Guidance for Industry “Bioanalytical Meth-
ods Validation for Human Studies”, U.S. Department of Health and 
Human Services.
Guan, F., Uboh, C.E., Soma, L.R., Birks, E.K., Teleis, D., Rudy, J.A., 
Watson, A.O. and Tsang, D.S. 2000. Quantiﬁ  cation of phenytoin and 
its metabolites in equine plasma and urine using high-performance 
liquid chromatography. J. Chromatogr., 746:209–18.
Leduc, B. 2002. Antiseizure Drugs, in Foye‘s Principles of Medicinal 
Chemistry, 5th edition. Philadelphia, Lippincot Williams and 
Wilkins, 384–404.
Lu-Steffes, M., Pittluck, G.W., JoIley, M.E., Panas, H.N., Olive, D.L., 
Wang, C.J., Nystrom, D.D., Keegan, C.L., Davis, T.P. and 
Stroupe, S.D. 1982. Fluorescence polarization immunoassay IV. 
Determination of phenytoin and phenobarbital in human serum and 
plasma. Clin. Chem., 28:2278–82.
Maya, M.T., Farinha, A.R., Lucas, A.M. and Morais, J.A. 1992. Sensitive 
method for the determination of phenytoin in plasma, and phenytoin 
and 5-(4-hydroxyphenyl)-5-phenylhydantoin in urine by high-
performance liquid chromatography. J. Pharm. Biomed. Anal., 
10:1001–6.
Melton, J.W. and Henze, H.R. 1947. Certain 5-(substitutedphenyl)-5-phen-
ylhydantoins. J. Am. Chem. Soc., 69:2018–20.
Moffat, A.C., Osselton, M.D. and Widdop, B. 2004. Clarke’s Analysis of Drugs 
and Poisons, on CD-ROM, Pharmaceutical Press, Publications division 
of the Royal Pharmaceutical Society of Great Britain. London.
Montouris, G. and Morris, G.L. 2005. Reproductive and sexual dysfunction 
in men with epilepsy. Epilepsy and Behavior, 7:S7–14.
Queiroz, M.E., Silva, S.M., Carvalho, D. and Lancas, F.M. 2002. Determi-
nation of lamotrigine simultaneously with carbamazepine, carbam-
azepine epoxide, phenytoin, phenobarbital, and primidone in human 
plasma by SPME-GC-TSD. J. Chromatogr. Sci., 40:219–23.
Rao, G.S. and Mclennon, D.A. 1977. Thin-layer chromatographic analy-
sis of phenytoin and its hydroxyl metabolites. J. Chromatogr., 
137:231–33.
Rezaei, Z., Hemmateenejad, B., Khabnadideh, S. and Gorgin, M. 2005. 
Simultaneous spectrophotometric determination of carbamazepine 
and phenytoin in serum by PLS regression and comparison with 
HPLC. Talanta, 65:21–18.
Simon, G.E., Jatlaw, P.I., Seligson, H.T. and Seligson, D. 1971. Measure-
ment of 5,5-diphenylhydantoin in blood using thin-layer chromatog-
raphy. Am. J. Clin. Pathol., 55:145–51.
Smaldone, M., Sukkarieh, T., Reda, A. and Khan, A. 2004. Epilepsy and 
erectile dysfunction: a review. Seizure, 13:453–9.
Stimmel, G.L. and Gutierrez, M.A. 2006. Pharmacological treatment strat-
egies for sexual dysfunction in patients with epilepsy and depression. 
CNS Spectr, 11(Suppl 9):31–7.
Vermeij, T.A.C. and Edelbroek, P.M. 2007. Robust isocratic high perfor-
mance liquid chromatographic method for simultaneous determina-
tion of seven antiepileptic drugs including lamotrigine, oxcarbazepine 
and zonisamide in serum after solid-phase extraction in press. J. 
Chromatogr. B.
Wang, J., Wang, Y., Fawcett, J.P., Wang, Y. and Gu, J. 2005. Determination 
of omeprazole in human plasma by liquid chromatography-
electrospray quadrupole linear ion trap mass spectrometry. J. Pharm. 
Biomed. Anal., 39:631–5.